RecruitingNCT06718257

Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Principal Investigator
Weilin Wang, PHD
Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University
Intervention
Gemcitabine combined with cisplatin or oxaliplatin(drug)
Enrollment
300 enrolled
Eligibility
18 years · All sexes
Timeline
2024 – 2025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06718257 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma →

← Back to all trials